Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain Sells 6,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $16.18, for a total transaction of $97,080.00. Following the transaction, the general counsel now directly owns 105,386 shares in the company, valued at $1,705,145.48. This trade represents a 5.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Centessa Pharmaceuticals Trading Down 0.7 %

NASDAQ:CNTA opened at $16.63 on Friday. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -10.87 and a beta of 1.53. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average of $16.71 and a 200 day moving average of $15.83.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on CNTA shares. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Large investors have recently made changes to their positions in the business. Janus Henderson Group PLC grew its stake in Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock worth $82,218,000 after buying an additional 3,614,623 shares during the last quarter. Foresite Capital Management VI LLC acquired a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $20,994,000. Franklin Resources Inc. grew its stake in shares of Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after acquiring an additional 1,145,823 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Centessa Pharmaceuticals by 54.1% during the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after acquiring an additional 953,659 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in shares of Centessa Pharmaceuticals by 22.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after purchasing an additional 924,027 shares during the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.